Literature DB >> 12270028

Management of premature ejaculation -- a comparison of treatment outcome in patients with and without erectile dysfunction.

Sing joo Chia1.   

Abstract

This study evaluated the problem of premature ejaculation (PE) in patients treated for erectile dysfunction. The aim was to compare the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the management of primary PE and PE associated with sildenefil treatment. Eighty-seven patients with PE seen over a period of 17 months were recruited into this prospective study. They were categorized into two groups: primary PE (GPI) and PE in sildenefil-treated patients (GPII). All patients recruited into GPII had erectile dysfunction (ED) that was successfully treated with sildenefil citrate for at least a year. Both groups of patients were given sertraline 50 mg 4 h before expected time of sex. The minimum follow-up was 6 months. The ejaculation latency before and after treatment of the two groups were compared. The sexual satisfaction scores of the patients in the two groups were also sought and analysed. Twenty-eight percent of patients with ED who were successfully treated with sildenefil developed PE. Subjects in group GPI were younger and have less comorbid factors than those in group GPII. There was no significant difference in the mean ejaculation latency for both groups (46 vs. 34.6 sec for GPI and GPII, respectively). However, there was highly significant difference in the ejaculation latency between the two groups after treatment with sertraline for 6 months (247.2 vs. 111.6 sec for GPI and GPII, respectively). There was also significant difference in the sexual satisfaction score for group GPI post-treatment, but not for GPII. No significant side-effect of sertraline was reported from patients in both groups. Successful treatment of ED could not assure sexual satisfaction. At least a quarter of sildenefil treated ED patients might develop PE which would continue to frustrate these patients sexually. While selective serotonin re-uptake inhibitors (SSRIs) was effective in the management of primary PE, they were not as effective in patients with sildenefil corrected ED.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270028     DOI: 10.1046/j.1365-2605.2002.00368.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  7 in total

Review 1.  Premature ejaculation: definition and drug treatment.

Authors:  Marcel D Waldinger
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Mucosal cuff length to penile length ratio may affect the risk of premature ejaculation in circumcised males.

Authors:  E Yuruk; M Z Temiz; A Colakerol; A Y Muslumanoglu
Journal:  Int J Impot Res       Date:  2015-12-24       Impact factor: 2.896

Review 3.  Treatment of premature ejaculation: new drugs and treatment strategies.

Authors:  Wayne J G Hellstrom; Jay W Heintz
Journal:  Curr Urol Rep       Date:  2006-11       Impact factor: 2.862

Review 4.  An Update of the International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE).

Authors:  Stanley E Althof; Chris G McMahon; Marcel D Waldinger; Ege Can Serefoglu; Alan W Shindel; P Ganesan Adaikan; Edgardo Becher; John Dean; Francois Giuliano; Wayne Jg Hellstrom; Annamaria Giraldi; Sidney Glina; Luca Incrocci; Emmanuele Jannini; Marita McCabe; Sharon Parish; David Rowland; R Taylor Segraves; Ira Sharlip; Luiz Otavio Torres
Journal:  Sex Med       Date:  2014-06       Impact factor: 2.491

5.  Relation of size of seminal vesicles on ultrasound to premature ejaculation.

Authors:  Zhi-Wei Hong; Yu-Ming Feng; Yi-Feng Ge; Jun Jing; Xue-Chun Hu; Jia-Ming Shen; Long-Ping Peng; Bing Yao; Zhong-Cheng Xin
Journal:  Asian J Androl       Date:  2017 Sep-Oct       Impact factor: 3.285

6.  Premature ejaculation.

Authors:  Chris G McMahon
Journal:  Indian J Urol       Date:  2007-04

Review 7.  Emerging and investigational drugs for premature ejaculation.

Authors:  Chris G McMahon
Journal:  Transl Androl Urol       Date:  2016-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.